| Symbol | CLDI |
|---|---|
| Name | CALIDI BIOTHERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 4475 EXECUTIVE DRIVE, SAN DIEGO, CA 92121 |
| Telephone | 858-794-9600 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001855485 |
| Description | None |
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Read moreCalidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Read more(99% Neutral) CALIDI BIOTHERAPEUTICS, INC. (CLDI) Announces Business Combination
Read moreNew Form 3 - Calidi Biotherapeutics, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001493152-26-031118 <b>Size:</b> 14 KB
Read moreCalidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Read more(80% Positive) CALIDI BIOTHERAPEUTICS, INC. (CLDI) Provides Update on record for developing new technologies
Read moreCalidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Read moreNew Form DEFA14A - Calidi Biotherapeutics, Inc. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001493152-26-027516 <b>Size:</b> 21 KB
Read more(99% Neutral) CALIDI BIOTHERAPEUTICS, INC. (CLDI) Announces Business Combination
Read more